What is Rosukaa?
Rosukaa (Rosukaa) belongs to a a group of drugs called HMG CoA reductase inhibitors, or "statins." Rosukaa reduces levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL).
Rosukaa is used in adults and children who are at least 8 years old to lower cholesterol and triglycerides (types of fat) in the blood and to slow the build-up of plaque (fatty deposits) in your blood vessels.
Rosukaa is also used to lower the risk of stroke, heart attack, and other heart complications in certain people with diabetes, coronary heart disease, or other risk factors.
Rosukaa is also used to treat hereditary forms of high cholesterol, including the heterozygous type (inherited from one parent) and the homozygous type (inherited from both parents). For the heterozygous type, Rosukaa can be used in children who are at least 8 years old. For the homozygous type, Rosukaa can be used in children as young as 7 years old.
Rosukaa indications
Rosukaa should be used as an adjunct to diet when the response to diet and exercise is inadequate.
Prevention of Cardiovascular Events: In adult patients with an increased risk of atherosclerotic cardiovascular disease based on the presence of cardiovascular disease risk markers such as an elevated hsCRP level, age, hypertension, low HDL-C, smoking or a family history of premature coronary heart disease, Rosukaa is indicated to reduce total mortality and the risk of major cardiovascular events (cardiovascular death, stroke, MI, unstable angina, or arterial revascularization).
In Adult Patients with Hypercholesterolaemia: Rosukaa is indicated to: Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDL-cholesterol in patients with primary hypercholesterolaemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). Rosukaa also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG, the LDL-C/HDL-C, total C/HDL-C, nonHDL-C/HDL-C, ApoB/ApoA-I ratios and increases ApoA-I in these populations.
Treat patients with primary dysbetalipoproteinaemia (Fredrickson Type III hyper lipoproteinaemia).
Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia).
Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolaemia, as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or alone if such treatments are unavailable.
Slow or delay the progression of atherosclerosis.
Children and Adolescents 6 to 17 Years of Age: Rosukaa is indicated to reduce the Total Cholesterol, LDL-C and Apo B in patients with heterozygous familial hypercholesterolaemia (HeFH).
How should I use Rosukaa?
Use Rosukaa as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Rosukaa. Talk to your pharmacist if you have questions about this information.
- Take Rosukaa by mouth with or without food.
- Swallow the tablets whole.
- If you also take an antacid that has aluminum or magnesium in it, take it at least 2 hours after taking Rosukaa. Check with your doctor if you have any questions.
- Taking Rosukaa at the same time each day will help you remember to take it.
- Continue to take Rosukaa even if you feel well. Do not miss any doses.
- If you miss a dose of Rosukaa, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once or within 12 hours of each other.
Ask your health care provider any questions you may have about how to use Rosukaa.
Uses of Rosukaa in details
- Rosukaa is used for the treatment of high cholesterol, high LDL, high triglycerides and low HDL in addition to diet, when response to non-medicine options (diet, exercise and weight loss) is not adequate.
- It is also used to lower the risk of stroke, heart attack, or other heart complications in people who are at high risk of heart diseases, as an adjuvant to correction of the risk factors.
Rosukaa description
Rosukaa also contains the following inactive ingredients: Tribasic calcium phosphate, microcrystalline cellulose (PH 102), butylated hydroxy toluene, povidone K-30, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Instacoat universal white IH, purified water; color: Titanium dioxide.
Rosukaa is a synthetic lipid-lowering agent for oral administration. The chemical name for Rosukaa calcium is bis[(E)-7-[4(4-fluorophenyl)-6-isopropyl 2[methyl (methylsulfonyl) amino] pyrimidin-5-yl](3R,5S)3,5-dihydroxyhept-6-enoic acid] calcium salt. The empirical formula is (C22H27FN3O6S)2Ca and the molecular weight is 1001.14.
Rosukaa dosage
General Dosing Information: The dose range for Rosukaa is 5-40 mg orally once daily.
Rosukaa can be administered as a single dose at any time of the day, with or without food. When initiating Rosukaa therapy or switching from another HMG-CoA reductase inhibitor therapy, the appropriate Rosukaa starting dose should first be utilized, and only then titrated according to the patient's response and individualized goal of therapy.
The 40 mg dose of Rosukaa should be used only for those patients who have not achieved their LDL-C goal utilizing the 20 mg dose.
Hyperlipidemia, Mixed Dyslipidemia, Hypertriglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) and Slowing of the Progression of Atherosclerosis: The recommended starting dose of Rosukaa is 10 mg dose once daily. For patients with marked hyperlipidemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20 mg starting dose may be considered.
After initiation or upon titration of Rosukaa, lipid levels should be analyzed within 2-4 weeks and the dosage adjusted accordingly.
Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years): The usual dose range of Rosukaa is 5-20 mg/day; the maximum recommended dose is 20 mg/day (doses >20 mg have not been studied in this patient population). Doses should be individualized according to the recommended goal of therapy. Adjustments should be made at intervals of ≥4 weeks.
Homozygous Familial Hypercholesterolemia: The recommended starting dose of Rosukaa is 20 mg once daily. Response to therapy should be estimated from pre-aphereses LDL-C levels.
Dosage in Asian Patients: Initiation of Rosukaa therapy with 5 mg once daily should be considered for Asian patients.
Use with Cyclosporine or Lopinavir/Ritonavir: In patients taking cyclosporine, the dose of Rosukaa should be limited to 5 mg once daily. In patients taking a combination of lopinavir and ritonavir, the dose of Rosukaa should be limited to 10 mg once daily.
Concomitant Lipid-Lowering Therapy: The risk of skeletal muscle effects may be enhanced when Rosukaa is used in combination with niacin or fenofibrate; a reduction in Rosukaa is used in combination with gemfibrozil, the dose of Rosukaa should be limited to 10 mg daily.
Dosage in Patients with Severe Renal Impairment: For patients with severe renal impairment (CrCl <30 mL/min/1.73 m2) not on hemodialysis, dosing of Rosukaa should be started at 5 mg once daily and should not exceed 10 mg once daily.
Rosukaa interactions
See also:
What other drugs will affect Rosukaa?
Effect of Co-Administered Medicinal Products on Rosukaa: In vitro and in vivo data indicate that Rosukaa has no clinically significant cytochrome P450 interactions (as a substrate, inhibitor or inducer). Rosukaa is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of Rosukaa with medicinal products that are inhibitors of these transporter proteins may result in increased Rosukaa plasma concentrations and an increased risk of myopathy.
Interactions Requiring Rosukaa Dose Adjustments : When it is necessary to co-administer Rosukaa with other medicinal products known to increase exposure to Rosukaa, doses of Rosukaa should be adjusted. It is recommended that prescribers consult the relevant product information when considering administration of such products together with Rosukaa. Start with a 5 mg once daily dose of Rosukaa if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of Rosukaa should be adjusted so that the expected Rosukaa exposure would not likely exceed that of a 40 mg daily dose of Rosukaa taken without interacting medicinal products, for example a 5 mg dose of Rosukaa with ciclosporin (7.1-fold increase in exposure), a 10 mg dose of Rosukaa with ritonavir/atazanavir combination (3.1-fold increase) and a 20 mg dose of Rosukaa with gemfibrozil (1.9-fold increase).
Other Interacting Medicinal Products: Antacid: The simultaneous dosing of Rosukaa with an antacid suspension containing aluminum and magnesium hydroxide resulted in a decrease in Rosukaa plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after Rosukaa. The clinical relevance of this interaction has not been studied.
Fusidic Acid: Interaction studies with Rosukaa and fusidic acid have not been conducted. As with other statins, muscle related events, including rhabdomyolysis, have been reported in post-marketing experience with Rosukaa and fusidic acid given concurrently. Patients should be closely monitored and temporary suspension of Rosukaa treatment may be appropriate.
Effect of Rosukaa on Co-Administered Medicinal Products: Warfarin: The pharmacokinetics of warfarin are not significantly affected following co-administration with Rosukaa. However, as with other HMG-CoA reductase inhibitors, co-administration of Rosukaa and warfarin may result in a rise in INR compared to warfarin alone. In patients taking vitamin K antagonists monitoring of INR is recommended both at initiation or cessation of therapy with Rosukaa or following dose adjustment.
Fenofibrates/Fibric Acid Derivatives: Although no pharmacokinetic interaction between Rosukaa and fenofibrate was observed; a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate and other fibric acids, including nicotinic acid, may increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors.
Cyclosporin: Co-administration of Rosukaa with cyclosporin resulted in no significant changes in cyclosporin plasma concentration.
Other Medications: There were no clinically significant interactions with an oral contraceptive, digoxin, ezetimibe, or fenofibrate.
In clinical studies Rosukaa was co-administered with antihypertensive agents, antidiabetic agents and hormone replacement therapy. These studies did not produce any evidence of clinically significant adverse interactions.
Rosukaa side effects
See also:
What are the possible side effects of Rosukaa?
Rosukaa is generally well tolerated. The adverse events seen with Rosukaa are generally mild and transient. In controlled clinical trials less than 4% of Rosukaa treated patients were withdrawn due to adverse events. This withdrawal rate was comparable to that reported in patients receiving placebo.
Common (≥1/100, <1/10): Headache, myalgia, asthenia, constipation, dizziness, nausea, abdominal pain, diabetes mellitus*.
Uncommon (≥1/1000, <1/100): Pruritus, rash and urticaria.
Rare (≥1/10,000, <1/1000): Myopathy (including myositis), hypersensitivity reactions (including angioedema), rhabdomyolysis, pancreatitis.
*Observed in the JUPITER study (reported overall frequency 2.8% in Rosukaa and 2.3% in placebo) primarily in patients already at high risk for developing diabetes.
As with other HMG CoA reductase inhibitors, the incidence of adverse drug reactions tends to increase with increasing dose.
Skeletal Muscle Effects: Rare cases of rhabdomyolysis, which were occasionally associated with impairment of renal function, have been reported with Rosukaa and with other marketed statins.
Laboratory Effects: As with other HMG-CoA reductase inhibitors, a dose-related increase in liver transaminases and CK has been observed in a small number of patients taking Rosukaa. Increases in HbA1c have also been observed in patients treated with Rosukaa. Abnormal urinalysis testing (dipstick-positive proteinuria) has been seen in a small number of patients taking Rosukaa and other HMG-CoA reductase inhibitors. The protein detected was mostly tubular in origin. In most cases, proteinuria decreases or disappears spontaneously on continued therapy, and is not predictive of acute or progressive renal disease.
Other Effects: In a long-term controlled clinical trial Rosukaa was shown to have no harmful effects on the ocular lens.
In Rosukaa treated patients, there was no impairment of adrenocortical function.
Post Marketing Experience: In addition to the previously mentioned effects, the following adverse events have been reported during post marketing experience of Rosukaa: Haematological Disorders: Frequency Unknown: Thrombocytopenia.
Hepatobiliary Disorders: Very Rare: Jaundice, hepatitis. Rare: Increased hepatic transaminases.
Musculoskeletal Disorder: Frequency Unknown: Immune-mediated necrotising myopathy. Very Rare: Arthralgia.
As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis in post-marketing use is higher at the highest marketed dose.
Nervous System Disorder: Very Rare: Memory loss. Frequency Unknown: Peripheral neuropathy.
Psychiatric Disorders: Frequency Unknown: Depression, sleep disorders (including insomnia and nightmares).
Reproductive System and Breast Disorders: Frequency Unknown: Gynaecomastia.
Children and Adolescents 6 to 17 Years of Age: The safety profile of Rosukaa is similar in children or adolescent patients and adults although CK elevations >10 x ULN and muscle symptoms following exercise or increased physical activity, which resolved with continued treatment, were observed more frequently in clinical trial of children and adolescents. However, the same special warnings and special precautions for use in adults also apply to children and adolescents.
Rosukaa contraindications
See also:
What is the most important information I should know about Rosukaa?
Hypersensitivity to Rosukaa or to any of the excipients of Rosukaa Sandoz.
Hepatic impairment; severe renal impairment; repeated or unexplained muscle aches or pain (myopathy); ciclosporin (eg, used after organ transplants).
In addition, the 40 mg dose of Rosukaa Sandoz is contraindicated in: Repeated or unexplained muscle aches or pains (myopathy), a personal or family history of muscle problems or a previous history of muscle problems when taking other cholesterol-lowering drugs; moderate renal impairment; thyroid gland disorders; regular consumption of large amounts of alcohol; if taking fibrates to lower cholesterol; Asian origin (Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).
Use in pregnancy & lactation: Rosukaa Sandoz should not be taken by pregnant and breastfeeding women. If the patient become pregnant while taking Rosukaa Sandoz, stop taking it immediately and inform the physician. Women should avoid becoming pregnant while taking Rosukaa Sandoz by using suitable contraception.
Active ingredient matches for Rosukaa:
| Unit description / dosage (Manufacturer) | Price, USD |
| ROSUKAA 10 MG TABLET 1 strip / 10 tablets each (Troikaa Pharmaceuticals Ltd) | $ 1.47 |
| ROSUKAA 20MG TABLET 1 strip / 10 tablets each (Troikaa Pharmaceuticals Ltd) | $ 2.92 |
| ROSUKAA 5 MG TABLET 1 strip / 10 tablets each (Troikaa Pharmaceuticals Ltd) | $ 0.84 |
| Rosukaa 10mg Tablet (Troikaa Pharmaceuticals Ltd) | $ 0.16 |
| Rosukaa 20mg Tablet (Troikaa Pharmaceuticals Ltd) | $ 0.32 |
| Rosukaa 40mg Tablet (Troikaa Pharmaceuticals Ltd) | $ 0.51 |
| Rosukaa 5mg Tablet (Troikaa Pharmaceuticals Ltd) | $ 0.08 |
| Rosukaa A 10/150 Capsule (Troikaa Pharmaceuticals Ltd) | $ 0.08 |
| Rosukaa A 10/75 Tablet (Troikaa Pharmaceuticals Ltd) | $ 0.07 |
| Rosukaa A 20/150 Capsule (Troikaa Pharmaceuticals Ltd) | $ 0.10 |
| Rosukaa Gold 75mg/10mg/75mg Capsule (Troikaa Pharmaceuticals Ltd) | $ 0.17 |
List of Rosukaa substitutes (brand and generic names): | |
| Rosuhol (Serbia) | |
| ROSUKEM | |
| ROSUKEM -10 TABLET 1 strip / 15 tablets each (Alkem Laboratories Ltd) | $ 1.29 |
| ROSUKEM -20 TABLET 1 strip / 10 tablets each (Alkem Laboratories Ltd) | $ 1.59 |
| ROSUKEM -20 TABLET 1 strip / 15 tablets each (Alkem Laboratories Ltd) | $ 2.61 |
| ROSUKEM 40MG TABLET 1 strip / 10 tablets each (Alkem Laboratories Ltd) | $ 2.77 |
| ROSUKEM 5 MG TABLET 1 strip / 10 tablets each (Alkem Laboratories Ltd) | $ 0.51 |
| ROSUKEM 5 MG TABLET 1 strip / 15 tablets each (Alkem Laboratories Ltd) | $ 0.76 |
| Rosukem 20mg Tablet (Alkem Laboratories Ltd) | $ 0.19 |
| Rosukem 40mg Tablet (Alkem Laboratories Ltd) | $ 0.28 |
| Rosukem 5mg Tablet (Alkem Laboratories Ltd) | $ 0.06 |
| ROSULESS (Georgia, India) | |
| ROSULESS 10 MG TABLET 1 strip / 10 tablets each (Corona (Wellness)) | $ 0.40 |
| ROSULESS 20 MG TABLET 1 strip / 10 tablets each (Corona (Wellness)) | $ 0.72 |
| ROSULESS 5 MG TABLET 1 strip / 10 tablets each (Corona (Wellness)) | $ 0.30 |
| ROSULESS tab 5 mg x 10's (Corona (Wellness)) | $ 0.30 |
| ROSULESS tab 10 mg x 10's (Corona (Wellness)) | $ 0.40 |
| ROSULESS tab 20 mg x 10's (Corona (Wellness)) | $ 0.72 |
| Rosuless 10mg Tablet (Corona (Wellness)) | $ 0.04 |
| Rosuless 20mg Tablet (Corona (Wellness)) | $ 0.08 |
| Rosuless 5mg Tablet (Corona (Wellness)) | $ 0.04 |
| Rosuless A 10mg/75mg Capsule (Corona (Wellness)) | $ 0.06 |
| Rosulex (India) | |
| Rosulex 5mg TAB / 10 (Unilex) | $ 0.47 |
| Rosulex 10mg TAB / 10 (Unilex) | $ 0.71 |
| ROSULEX tab 5 mg x 10's (Unilex) | $ 0.47 |
| ROSULEX tab 10 mg x 10's (Unilex) | $ 0.71 |
| Rosulib (Brazil) | |
| Rosulife | |
| Rosulife 10mg Tablet (Orris Pharmaceuticals) | $ 0.13 |
| Rosulife 20mg Tablet (Orris Pharmaceuticals) | $ 0.21 |
| Rosuline (India) | |
| Rosuline 5mg TAB / 10 (Johnlee (Vista)) | $ 1.93 |
| Rosuline 10mg TAB / 10 (Johnlee (Vista)) | $ 2.53 |
| Rosuline 20mg TAB / 10 (Johnlee (Vista)) | $ 3.55 |
| ROSULINE tab 5 mg x 10's (Johnlee (Vista)) | $ 1.93 |
| ROSULINE tab 10 mg x 10's (Johnlee (Vista)) | $ 2.53 |
| ROSULINE tab 20 mg x 10's (Johnlee (Vista)) | $ 3.55 |
| ROSULINE tab 40 mg x 10's (Johnlee (Vista)) | $ 4.39 |
| ROSULIP (Georgia) | |
| 10 mg x 10's (Cipla) | $ 1.19 |
| 40 mg x 10's (Cipla) | $ 3.37 |
| Rosulip 5mg TAB / 10 (Cipla) | $ 0.67 |
| Rosulip 10mg TAB / 10 (Cipla) | $ 1.19 |
| Rosulip 20mg FC-TAB / 10 (Cipla) | $ 1.81 |
| Rosulip 40mg FC-TAB / 10 (Cipla) | $ 3.37 |
| ROSULIP 10 MG TABLET 1 strip / 15 tablets each (Cipla) | $ 2.30 |
| ROSULIP 20 MG TABLET 1 strip / 10 tablets each (Cipla) | $ 2.33 |
| ROSULIP 40 MG TABLET 1 strip / 10 tablets each (Cipla) | $ 4.37 |
| ROSULIP 5 MG TABLET 1 strip / 15 tablets each (Cipla) | $ 1.31 |
| ROSULIP CP 10 MG TABLET 1 strip / 15 tablets each (Cipla) | $ 2.30 |
| ROSULIP film-coated tab 5 mg x 10's (Cipla) | $ 0.67 |
| ROSULIP film-coated tab 10 mg x 10's (Cipla) | $ 1.27 |
| ROSULIP film-coated tab 20 mg x 10's (Cipla) | $ 1.93 |
| ROSULIP film-coated tab 40 mg x 10's (Cipla) | $ 3.61 |
| Rosulip 5mg TAB / 10 (Cipla) | $ 0.67 |
| Rosulip 10mg TAB / 10 (Cipla) | $ 1.19 |
| Rosulip 20mg FC-TAB / 10 (Cipla) | $ 1.81 |
| Rosulip 40mg FC-TAB / 10 (Cipla) | $ 3.37 |
| Rosulip 10mg Tablet (Cipla) | $ 0.15 |
| Rosulip 20mg Tablet (Cipla) | $ 0.26 |
| Rosulip 40mg Tablet (Cipla) | $ 0.48 |
| Rosulip 5mg Tablet (Cipla) | $ 0.10 |
| Rosulip 10 (Paraguay) | |
| Rosulip 20 (Paraguay) | |
See 2029 substitutes for Rosukaa | |
References
- DailyMed. "ROSUVASTATIN CALCIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "ASPIRIN; DIPYRIDAMOLE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "clopidogrel". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Rosukaa are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Rosukaa. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet2 consumers reported age
| Users | % | ||
|---|---|---|---|
| 46-60 | 1 | 50.0% | |
| > 60 | 1 | 50.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
